Our Research

Research in the Department of Neurology has grown by leaps and bounds in recent years. Between FY14 and FY16, the total sponsored research dollars grew by over 180%. Total research dollars awarded in FY16 topped $4.8 million.

Research

The VCU Department of Neurology is home to an active clinical and translational research program with National Institutes of Health (NIH)- and major foundation-funded projects and numerous ongoing clinical trials across all divisions.

NCTRO

The Neurology Clinical and Translational Research Office (NCTRO)

The NCTRO provides comprehensive support to investigators in the Department of Neurology. We have a team of specialists with expertise in research financial management, clinical research operations and Institutional Review Board (IRB) compliance who work with our principal investigators to obtain funding, assist with trial preparations and daily operations of their clinical trials.  

The research office is available to support the department’s researchers in study startup, grant submission, study coordination and regulatory matters.  

Research Faculty

Department of Neurology research faculty

Nicholas E. Johnson, M.D., M.Sci., FAAN [View Image]

Nicholas E. Johnson, M.D., M.Sci., FAAN

Vice Chair for Research

Nicholas E. Johnson, M.D., M.Sci., FAAN [View Image]

Nicholas E. Johnson, M.D., M.Sci., FAAN

Vice Chair for Research

Department of Neurology

Divisions: Adult Neurology, Neuromuscular
Vice Chair, Research
Associate Professor

Email: nicholas.johnson@vcuhealth.org

Read More

View Faculty Expertise Profile

Active Projects

The VCU Department of Neurology is home to an active clinical and translational research program with National Institutes of Health (NIH)- and major foundation-funded projects and numerous ongoing clinical trials across all divisions.

Currently, the Department of Neurology has more than 40 active clinical trials or research projects across disciplines. The department is ranked 45th in federal funding with nearly $3 million in grants. Projects in neurology span the research space with basic, translational and industry-sponsored clinical trials across multiple disciplines. 

Clinical Trial 

Funding Sponsor  

Eye tracking as a biomarker for manifest and Parkinson's disease  

Michael J Fox Foundation for Parkinson’s Research  

Randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations  

Impax Laboratories, Amneal Pharmaceuticals  

Registry for the advancement of deep brain Stimulation in Parkinson's Disease  

NeuroPoint Alliance  

Overcoming impaired gastrointestinal motility in Parkinson’s disease: a pilot study of RQ-00000010  

Michael J Fox Foundation for Parkinson’s Research  

A multicenter global observational study to collect information on safety and to document the drug utilization of Tecfidera when used in routine medical practice in the treatment of MS  

Biogen Idec Inc.  

Plegridy observational program  

Biogen Idec Inc.  

A multicenter randomized double-blind placebo controlled phase 3 study to evaluate the efficacy and safety or SA237 as monotherapy in patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD)  

Chugai Pharmaceutical  

A multicenter randomized double-blind placebo controlled parallel group pilot to assess the efficacy and safety of H.P. Acthar in subjects with relapsing remitting MS 

INO Therapeutics/Mallinckrodt Pharmaceuticals 

Topiramate as a disease modifying therapy for cryptogenic sensory peripheral neuropathy in metabolic syndrome (CSPN)  

NeuroNext/National Institutes of Health  

A retrospective and prospective review of physical examination findings among neuromuscular patients, including ALS, seen at VCU ALS clinic  

VCU Department of Neurology  

Neuro-bank natural history study of als and other motor neuron disorders  

VCU Department of Neurology  

Surgical IIH treatment trial  

National Institutes of Health  

Randomized double-blind placebo global phase 3 study of edasalonexent in pediatric patients with DMD  

Catabasis Pharmaceuticals   

Phase 3 randomized double-blind placebo multicenter study to evaluate the efficacy and safety of givinostat in ambulant patients with DMD  

Italafarmaco SpA 

Phase IIb randomized, double-blind, parallel group, placebo- and active-controlled study with double-blind extension to assess the efficacy and safety of vamorolone in ambulant boys with duchenne muscular dystrophy (DMD)  

Reveragen BioPharma  

Open-label expanded access protocol for boys with DMD who have completed the long-term extension VBP15-LTE or VBP15-004  

Reveragen BioPharma  

Phase 2 open-label extension to assess the safety and efficacy of NS-065/NCNP-01 in boys with DMD  

NS Pharma, Inc  

Randomized, open-label, 

Randomized, open-label, prospective multicenter study of single vs. multiple Privigen dose regimens in pediatric CIDP  

CSL Behring  

A global study of a single one time dose of avxs 101 delivered to infants with genetically diagnosed and presymptomatic SMA with multiple copies of SMN2  

AveXis  

Prospective long-term registry of patients with diagnosis of SMA  

AveXis   

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1  

Myotonic Dystrophy Clinical Research Network   

Vertex myotonic dystrophy blood/tissue donation  

Vertex Pharmaceuticals  

Trial readiness and endpoint assessment in congenital myotonic dystrophy   

Muscular Dystrophy Association & National Institutes of Health  

Defining clinical endpoints in limb girdle muscular dystrophy  

National Institutes of Health  

Survey analysis of the systematic domains most relevant to limb girdle muscular dystrophy patients and family members  

National Institutes of Health  

Patient-focused survey to assess a proposed clinical study design in patients with facioscapulohumeral dystrophy (FSHD)  

Fulcrum Therapeutics  

FSHD longitudinal biomarker preparatory study  

Fulcrum Therapeutics  

Clinical trial readiness to solve barriers to drug development in FSHD  

University of Kansas Medical Center  

Phase 2 randomized, double-blind, placebo-controlled study of ACE-083 in Patients with Charcot-Marie-Tooth disease types 1 and X  

Acceleron Pharma  

an open-label extension study to investigate the safety of cannabidiol in children and adults with inadequately controlled Dravet or Lennox-Gastaut syndromes  

GW Pharmaceuticals 

The MS Data Registry/Tissue Bank  

VCU Department of Neurology  

Consequences of Prolonged Febrile Seizures in Children  

National Institutes of Health  

Multicenter open label crossover study to assess the pk and safety of diazepam buccal soluble film in pediatric subjects with epilepsy  

Aquestive Therapeutics  

Open-label safety and tolerability study of chronic intermittent use of diazepam buccal soluble film in pediatric, adolescent and adult subjects with epilepsy  

Aquestive Therapeutics  

Chemotherapy-induced peripheral neuropathy NH study  

Disarm Therapeutics  

Signal: Phase 2 multicenter, randomized, double-blind, placebo-controlled study in subjects with late prodromal and early manifest Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503  

Huntington Study Group  

Enroll-HD: Prospective registry study in a global Huntington’s disease (HD) cohort  

CHDI Foundation  

Dystonia Coalition projects  

National Institute of Neurological Disorders and Stroke   

Humanitarian use of diaphragm pacer for ALS  

Synapse BioMedical  

 

View graphic versionView graphic version